About 89bio
89bio is a company based in San Francisco (United States) founded in 2018. 89bio has raised $60 million across 1 funding round from investors including Orbimed, RA Capital and Longitude Capital. The company has 93 employees as of December 31, 2024. 89bio offers products and services including Pegozafermin. 89bio operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter San Francisco, United States
- Employees 93 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name 89Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$367.08 M (USD)-158.16as on Dec 31, 2024
-
EBITDA
-$384.62 M (USD)-154.83as on Dec 31, 2024
-
Total Equity Funding
$60 M (USD)
in 1 rounds
-
Latest Funding Round
$60 M (USD), Series A
Oct 25, 2018
-
Investors
Orbimed
& 3 more
-
Employee Count
93
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of 89bio
89bio is a publicly listed company on the NASDAQ with ticker symbol ETNB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of 89bio
89bio offers a comprehensive portfolio of products and services, including Pegozafermin.
Investigational drug for treating MASH and severe hypertriglyceridemia in patients.
People of 89bio
Unlock access to complete
Unlock access to complete
Funding Insights of 89bio
89bio has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series A round of $60 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 89bio
89bio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Longitude Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked |
Investor details for 89bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 89bio
Investment portfolio details for 89bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 89bio
Detailed financials for 89bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
89Bio Comparisons
Peer comparison for 89bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 89bio
89bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
Detailed competitors of 89bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 89Bio
Complete news archive for 89bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 89bio
89bio was founded in 2018.
89bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Rohan Palekar is the current CEO of 89bio.
89bio is a funded company, having raised a total of $60M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at 89bio is 93.
89bio is developing therapies for treating nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. The lead candidate is BIO89-100, which is a long-acting glycopegylated fibroblast growth factor 21 analog used for treating NASH. They have developed the product from their proprietary glycopegylation technology. The candidate is in phase I clinical trial.
89bio's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
89bio offers Pegozafermin.
Yes, 89bio is publicly traded on NASDAQ under the ticker symbol ETNB.
89bio has 4 investors. Key investors include Orbimed, RA Capital, Longitude Capital, and Pontifax Venture Capital.
The ticker symbol of 89bio is ETNB on NASDAQ.